Thienopyrimidine-based inhibitors of the Src family
US6503914B1 · kind B1 · utility
37Cited by
4References
99Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 23, 2000 |
| Grant date | Jan 7, 2003 |
| Priority date | — |
| Expiry date | Oct 23, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P37/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.